Standard induction therapy with lenalidomide, bortezomib, and dexamethasone did not overcome inferior outcomes in patients ...

In recent clinical trials, CAR-T cell therapies have shown significant efficacy in patients with relapsed/refractory multiple myeloma, offering a new potential treatment for those who have ...

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not ...

The publication of the pricing and reimbursement decision for Pepaxti (melflufen) in the Gazetta Ufficiale removes the last ...

Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ...

Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.

Study finds low peripheral blood lymphocyte count at diagnosis predicts worse overall survival in multiple myeloma patients.

The panelist discusses how real-world evidence for CAR T in relapsed/refractory multiple myeloma shows promising efficacy but ...

Paris: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products ...

Panelists discuss how to optimize treatment selection and sequencing for a 65-year-old patient with standard-risk, transplant ...

Peripheral blood absolute lymphocyte count at diagnosis is an effective biomarker that can be used to risk-stratify patients with multiple myeloma, according to retrospective study results.Continued ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...